Saturday, June 25, 2022

Insider Selling: PETERS WILLIAM J, Amphastar Pharmaceuticals Inc. [AMPH] CFO, EVP & Treasurer divested 5,512 shares

Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Amphastar Pharmaceuticals Inc. shares valued at $176,682 were sold by PETERS WILLIAM J on Jun 17. At $32.05 per share, PETERS WILLIAM J sold 5,512 shares. The insider’s holdings dropped to 100,480 shares worth approximately $3.19 million following the completion of this transaction.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored


Also, Lee Howard sold 10,291 shares, netting a total of over 388,859 in proceeds. Following the sale of shares at $37.79 each, the insider now holds 138,776 shares.

Before that, Petersen Floyd F. had sold 500 shares from its account. In a trade valued at $18,499, the Director traded Amphastar Pharmaceuticals Inc. shares for $37.00 each. Upon closing the transaction, the insider’s holdings decreased to 500 shares, worth approximately $2.73 million.

As published in a research note from Piper Sandler on January 07, 2022, Amphastar Pharmaceuticals Inc. [AMPH] has been rated up from a Neutral to an Overweight and the price target has been revised to $28 from $21. This represents a -13.25% premium over Wednesday’s closing price. Analysts at Wells Fargo downgraded the stock from ‘”an Overweight”‘ to ‘”an Equal weight”‘ outlook in a report released in early January. As of October 05, 2020, Northland Capital has increased its “Market perform” rating to a “an Outperform” for AMPH. Earlier on May 01, 2020, Northland Capital initiated its rating. Their recommendation was “an Outperform” for AMPH stock.

Analyzing AMPH’s Price Performance

On Wednesday, Amphastar Pharmaceuticals Inc. [NASDAQ: AMPH] rose 0.32% to $31.71. The stock’s lowest price that day was $31.30, but it reached a high of $32.38 in the same session. During the last five days, there has been a surge of approximately 2.22%. Over the course of the year, Amphastar Pharmaceuticals Inc. shares have jumped approximately 36.15%. Shares of the company reached a 52-week high of $44.46 on 04/14/22 and a 52-week low of $22.07 on 01/31/22. A 50-day SMA is recorded $35.60, while a 200-day SMA reached $27.06. Nevertheless, trading volume fell to 0.36 million shares from 0.42 million shares the previous day.

Support And Resistance Levels for Amphastar Pharmaceuticals Inc. (AMPH)

According to the 24-hour chart, there is a support level at 31.21, which, if violated, would cause prices to drop to 30.72. In the upper region, resistance lies at 32.29. The next price resistance is at 32.88. RSI (Relative Strength Index) is 42.44 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -2.07, which suggests the price will decrease in the coming days. Percent R is at 77.54%, indicating bearish price movement. Stochastics %K at holding indicates that the stock is to be held.

Is Amphastar Pharmaceuticals Inc. subject to short interest?

Stocks of Amphastar Pharmaceuticals Inc. saw a sharp rise in short interest on Apr 28, 2022 jumping by 0.4 million shares to 2.35 million. Data from Yahoo Finance shows that the short interest on Mar 30, 2022 was 1.95 million shares. A jump of 17.02% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 4.71 of the overall float, the days-to-cover ratio (short ratio) jumped to 4.71.

Which companies own the most shares of Amphastar Pharmaceuticals Inc. (AMPH)?

According to BlackRock Fund Advisors filings, the company currently owns 6,015,882 shares, which is about 12.32% of the total AMPH shares outstanding. The investor’s shares have plunged by -135,561 from its previous 13-F filing of 6151443.0 shares. With the completion of the sale, Federated Global Investment Manag’s stake is now worth $122,557,766. The Vanguard Group, Inc. acquire a 0.75% interest valued at $89.7 million while Dimensional Fund Advisors LP purchased a 25,418 stake. A total of -117,256 shares of Amphastar Pharmaceuticals Inc. were bought by SSgA Funds Management, Inc. during the quarter, and 37,497 were bought by Invesco Capital Management LLC. In its current portfolio, Geode Capital Management LLC holds 703,479 shares valued at $26.13 million.

In terms of Amphastar Pharmaceuticals Inc. share price expectations, FactSet research, analysts set an average price target of $41.00 in the next 12 months, up nearly 29.71% from the previous closing price of $31.61. Analysts anticipate Amphastar Pharmaceuticals Inc. stock to reach $45.00 by 2022, with the lowest price target being $37.00. In spite of this, 4 analysts ranked Amphastar Pharmaceuticals Inc. stock as a Hold at the end of 2022. On March 13, 2019, Piper Jaffray assigned a price target of “a Neutral” to the stock and downgraded coverage with a $23.

Latest news

Related news

LEAVE A REPLY

Please enter your comment!
Please enter your name here

2618

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

The 5 Best Growth Stocks 2022

100% free. stop anytime no spam